Synapse PACS - Radiological Image Processing System - Product Usage: intended for use, as a web b...

FDA Device Recall #Z-1348-2021 — Class II — March 2, 2021

Recall Summary

Recall Number Z-1348-2021
Classification Class II — Moderate risk
Date Initiated March 2, 2021
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Fujifilm Medical Systems U.S.A., Inc.
Location Lexington, MA
Product Type Devices
Quantity 839 systems

Product Description

Synapse PACS - Radiological Image Processing System - Product Usage: intended for use, as a web based application, on an off-the-shelf PC meeting or exceeding minimum specifications and networked with FUJIFILM Synapse PACS Software (Server).

Reason for Recall

The wrong patient information may be displayed in the viewer or PowerJacket.

Distribution Pattern

Worldwide distribution - US Nationwide distribution including in the states of AZ, CA, CO, CT, DC, FL, GA, HI, IA, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, NE, NH, NJ, NV, NY, OH, OK, OR, PA, PR, RI, SC, SD, TN, TX, VA, VT, WA, WI, WV, WY and the countries of United Arab Emirates, Angola, Argentina, Austria, Australia, Belgium, Bermuda, Brazil, Canada, Switzerland, Chile, Colombia, Costa Rica, Czechia, Germany, Spain, Finland, France, United Kingdom, Greece, Guatemala, Hong Kong, Indonesia, Israel, India, Italy, Jordan, Japan, Kuwait, Malta, Mexico, Malaysia, Netherlands, Peru, Philippines, Pakistan, Poland, Portugal, Russia, Saudi Arabia, Singapore, Slovenia, Slovakia, El Salvador, Thailand, Turkey, Uruguay, South Africa, Zimbabwe.

Lot / Code Information

Software version: 5.1 to 5.7.200

Other Recalls from Fujifilm Medical Systems U.S.A., Inc.

Recall # Classification Product Date
Z-1775-2021 Class II Synapse Cardiovascular (Synapse CV). Software... Apr 30, 2021
Z-1412-2021 Class II ¿TASWako Chip Cassette is part of the Wako ¿TAS... Feb 18, 2021
Z-0932-2021 Class III Wako HDL-C/LDL-C Calibrator - Product Usage: de... Dec 22, 2020
Z-0918-2021 Class II FUJIFILM Synapse PACS Software: versions 7.0.0 ... Dec 11, 2020
Z-0282-2021 Class II Synapse PACS Software Version 5.6.1 - Product U... Sep 11, 2020

Frequently Asked Questions

Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.